Literature DB >> 29234259

Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Antonio B Porcaro1, Salvatore Siracusano1, Nicolò de Luyk1, Paolo Corsi1, Marco Sebben1, Alessandro Tafuri1, Tania Processali1, Davide Inverardi1, Giovanni Cacciamani1, Daniele Mattevi1, Maria A Cerruto1, Matteo Brunelli2, Claudio Ghimenton2, Carmelo Monaco1, Walter Artibani1.   

Abstract

OBJECTIVES: To evaluate the potential relations of simultaneous measurements of basal levels of follicle stimulating hormone (FSH) and total testosterone (TT) in clinically localized prostate cancer (PCa).
MATERIALS AND METHODS: The study included 126 patients who had simultaneous measurements of prostate specific antigen (PSA), FSH, and TT before undergoing radical prostatectomy for clinically localized PCa. Correlations and independent associations between clinical and pathological factors were investigated by statistical methods.
RESULTS: The tumor volume (TV) was directly correlated to PSA and TT which was inversely related to FSH. Moreover, it was independently associated with both PSA and TT. In a multivariate linear regression model, FSH and TV were simultaneous independent factors associated with TT, and the association was inverse in the former and direct in the latter. In the patient population, the subset with FSH levels above the third quartile was related to lower median levels of TT that were associated with high grade cancer showing a lower TV. In localized PCa, basal levels of TT were associated with tumor parameters and inversely related to FSH levels, and the subset FSH levels above the third quartile were related to lower TT levels that were associated with high grade cancers showing a lower tumor load.
CONCLUSION: Preoperative TT was associated with tumor parameters and inversely related to FSH levels. Patient with increased FSH levels was related to lower levels of TT, which was associated with high grade cancer.

Entities:  

Keywords:  Endocrine axis; Follicle stimulating hormone; Prostate cancer; Serum testosterone; Tumor grade; Tumor volume

Year:  2017        PMID: 29234259      PMCID: PMC5704728          DOI: 10.1159/000447177

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  39 in total

1.  Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.

Authors:  Takashi Imamoto; Hiroyoshi Suzuki; Satoshi Fukasawa; Masaki Shimbo; Masahiko Inahara; Akira Komiya; Takeshi Ueda; Taizo Shiraishi; Tomohiko Ichikawa
Journal:  Eur Urol       Date:  2004-12-29       Impact factor: 20.096

2.  The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.

Authors:  Jiri Heracek; Michael Urban; Jana Sachova; Jitka Kuncova; Vaclav Eis; Vaclav Mandys; Richard Hampl; Luboslav Starka
Journal:  Neuro Endocrinol Lett       Date:  2007-02       Impact factor: 0.765

Review 3.  Prognostic value of serum markers for prostate cancer.

Authors:  Ulf-Håkan Stenman; Per-Anders Abrahamsson; Gunnar Aus; Hans Lilja; Chris Bangma; Freddie C Hamdy; Laurent Boccon-Gibod; Peter Ekman
Journal:  Scand J Urol Nephrol Suppl       Date:  2005-05

4.  Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate.

Authors:  V L Kumar; S N Wadhwa; V Kumar; A Farooq
Journal:  J Surg Oncol       Date:  1990-06       Impact factor: 3.454

5.  Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.

Authors:  Dylan Hoare; Thomas A A Skinner; Angela Black; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

6.  The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.

Authors:  J M Monda; R P Myers; D G Bostwick; J E Oesterling
Journal:  Urology       Date:  1995-07       Impact factor: 2.649

7.  Radical prostatectomy: influence on serum and urinary androgen levels.

Authors:  Mats Olsson; Lena Ekström; Jenny Schulze; Anders Kjellman; Olof Akre; Anders Rane; Ove Gustafsson
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

8.  Testosterone levels in benign prostatic hypertrophy and prostate cancer.

Authors:  Luigi Mearini; Elisabetta Costantini; Alessandro Zucchi; Ettore Mearini; Vittorio Bini; Emanuele Cottini; Massimo Porena
Journal:  Urol Int       Date:  2008-03-19       Impact factor: 2.089

9.  Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.

Authors:  Antonio B Porcaro; Filippo Migliorini; Aldo Petrozziello; Teodoro Sava; Mario Romano; Beatrice Caruso; Claudio Cocco; Claudio Ghimenton; Stefano Zecchinini Antoniolli; Vincenzo Lacola; Emanuele Rubilotta; Carmelo Monaco; Luigi Comunale
Journal:  Urol Int       Date:  2012-11-02       Impact factor: 2.089

10.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  1 in total

1.  Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Authors:  Kassim Kourbanhoussen; France-Hélène Joncas; Christopher J D Wallis; Hélène Hovington; François Dagenais; Yves Fradet; Chantal Guillemette; Louis Lacombe; Paul Toren
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.